New Treatment for Adult B-Cell Acute Lymphoblastic Leukemia
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests a combination of targeted immunotherapy (a drug that helps your immune system fight cancer) plus low-dose chemotherapy for adults newly diagnosed with a specific type of blood cancer called Ph-negative B-ALL. The goal is to see if this approach can work better than standard treatments while being easier on your body.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 18 years old and newly diagnosed with Ph-negative B-cell acute lymphoblastic leukemia (a type of blood cancer)
- Your cancer cells must express a protein called CD22 (at least 20% of your cells must have it)
- You must be expected to live at least 3 more months
- If you can have children, you must agree to use reliable birth control during the study
- You must be able to understand the study, sign consent, and follow the treatment plan
- You cannot have certain serious infections, liver disease, heart rhythm problems, or hepatitis B/C/HIV
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of low-dose chemotherapy and immune-targeted drugs for adults newly diagnosed with a specific type of leukemia. The goal is to find a treatment that is effective with fewer side effects.
This trial tests giving chemotherapy together with a special immune cell treatment called CAR-T cells for adults who have just been diagnosed with a specific type of leukemia (Ph- B-ALL). The goal is to see if this combination works better than standard treatment.
This trial tests a combination of immunotherapy (using the immune system to fight cancer) and chemotherapy in adults aged 15–65 with newly diagnosed B-cell acute lymphoblastic leukemia (B-ALL), a blood cancer. The goal is to see if this combination helps patients achieve remission and survive longer.
This trial tests a sequence of three drugs for adults with newly diagnosed B-cell acute lymphoblastic leukemia (ALL) that does not have the Philadelphia chromosome. The goal is to see if this approach can better treat the leukemia.
This early-phase trial studies how well a targeted drug (inotuzumab ozogamicin) combined with chemotherapy treats acute lymphoblastic leukemia (ALL). It may help people with newly diagnosed ALL who may not tolerate standard intensive chemotherapy, especially older adults.
This trial tests a combination of targeted and chemotherapy medicines as first treatment for newly diagnosed B-cell acute lymphoblastic leukemia (ALL) or related lymphoblastic lymphoma. It aims to improve how well treatment controls the leukemia and how long people can stay in remission.
Hear when a new Ph- Acute Lymphoblastic Leukemia (Ph-ALL) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.